NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Old Version 1

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

compared with

New Version Current

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Anchor
maincontent
maincontent

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Kim, Erika (NIH/NCI) [E] X
Toby HechtX
Connie SommersX
Amy Leblanc
X
Igor KuzminX
Warren KibbeX
Matthew BreenX
Michael OlinX

...

Goals

  • Discuss the next 5 years for ICDC in preparation of the new task order

Discussion items

ItemWhoNotes
Integrating environmental exposures of human cancer patients with canines

Matthew Breen 

  • Human urothelial cancers cancer patients with dogs that live in their homes
  • Dog omics that share the same environmental exposure exposures as a human individual with cancer
  • Longitudinal studies across these dogs
  • Having an integrated canine commons at the NCI can be a hub for federal and privately funded studies
  • Signatures of lung cancers of smokers vs. someone exposed to smoke, can be validated using canines
  • Toxic compounds in clothing, canines may be exposed to same factors in home
  • Toxic compounds from fires, related to climate change
Cellular Data (Flow Cytometry, Nano String Data)Michael Olin
  • Raw data from the flow cytometer so that people can generate their own plots
  • How can subsets be looked at
Workshop for Immuno-Oncolgy (IO) Data Analytics Erika Kim
  • IO data for humans and canines
Non-Cancer Diseases

Toby Hecht


Pharma-specific Focus Group or Interviews

Amy Leblanc

  • Certain tools and data
  • Immune landscape
  • Comparative nanostring Nano-string IO cell landscapes
  • Landscape of IHC, Flowflow, and tools in specific canine tissues and cell types
  • Pharma needs to see placebo groups and to inspect efficacy signals with a set of retractable biomarkers
  • Pharma is looking for supplemental animal model
  • Jax labs may have some immunological data to submit
  • Dose optimization strategies
  • What does the FDA want to see as they are getting more molecularly targeted agents

Minutes (Not Verbatim)

Toby - We don't have sequencing data for comparing before and after therapy to detect genomic changes

Amy - I think Debbie Knapp has this data showing a transcriptional shift in BRAF-mutant bladder cancer

Toby - There has been a suggestion to go beyond cancer and involve other institutes particularly if they can help with funding. Also the Dog Aging project that looks at normal dogs until end of life and some of them develop tumors and the NCI is willing to co-fund sequencing on these tumors as they arise, we . We are waiting to hear back from Aging Institute, other thing is investigating environmental exposures in relation to to tumors. Let's derive a list of interesting topictopics.

Warren -  Representing Representing the life trajectory of the dogs, attaching the specimens and data derived from those specimens at the appropriate point in that dog's life would be valuable. The pre and post- treatment specimens are one example (genomics, proteomics, microbiome). Let's say we have measurements from when the dog is born vs. end of life, how can we represent that data to better understand the trajectory of their lives and also carcinogenesis if applicable. Can we prepare the ICDC for hosting this type of data?

Toby and all – What immuno-oncology data to support. Several kinds of data are possible: Nanostring/sequence, immunohistochemistry (immune cell infiltration into tumor microenvironment), flow cytometry (immune cell subsets), serum cytokine levels. For flow cytometry, should raw data files be submitted, which would allow ICDC users to analyze data and draw gates themselves or should processed data be submitted, which would take up less space?

Toby - ICDC is a node in the CRDC so not sure non-cancer data is relevant. Aging and NEHES are the closest partners to us to focus on cancer, it will be a stretch to do other things.

Amy - Friend from Bristol Meyers Squib reached out to better understand relationsips relationships with pharma, maybe we should put together a panel of pharma folks to see if they can have a focus group to determine data and tooling that would be useful to that community.

Action items

  •  Erika to invite Toby and Connie to Immuno-Oncology Workshop
  •  Toby to speak to Marc Ernstoff about submitting/storing IO data